ALK and non-small cell lung carcinoma: In the Phase III ALEX study of alectinib versus crizotinib in patients with advanced ALK‐fp NSCLC, although patients with high baseline cfDNA showed high response rates to targeted therapy, duration of response was much lower than observed for those with low baseline cfDNA [35].